3:45 AM
 | 
Dec 06, 2018
 |  BC Extra  |  Financial News

Impel raises $67.5M series D

Impel NeuroPharma Inc. (Seattle, Wash.) hopes to accelerate its clinical portfolio of intranasal CNS therapies with a $67.5 million series D round led by new investors KKR and Norwest Venture Partners.

Existing investors 5AM Ventures, Vivo Capital and venBio also participated in the round.

Impel is developing formulations of generic medicines for CNS disorders for intranasal delivery via its Precision Olfactory Delivery device. Its clinical pipeline includes lead candidate, INP104, a liquid formulation of dihydroergotamine (DHE) mesylate in Phase III testing for migraines; INP103, a levodopa powder in Phase II testing for Parkinson's disease; and INP105, an olanzapine powder in Phase I testing for bipolar disorder and schizophrenia.

Norwest's Robert Mittendorff and KKR's Ali Satvat will join Impel's board.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD